SOUTH SAN FRANCISCO, Calif., Dec. 6, 2012 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the launch of the Make Your Mark at the Multiple Myeloma Experience at the 54th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta, Georgia on December 8, 2012. The experience is designed to celebrate progress made in the treatment of multiple myeloma, an incurable blood cancer, and encourage members of the multiple myeloma community to make their mark by pledging their commitment to continue the momentum in advancing progress.For every pledge made at the Make Your Mark booth atASH, Onyx will make a charitable contribution to the International Myeloma Foundation (IMF) and Multiple Myeloma Research Foundation (MMRF).
To view the multimedia assets associated with this release, please click: http://www.multivu.com/mnr/59299-onyx-pharmaceuticals-make-your-mark-at-the-multiple-myeloma-experience
"Advances in the past decade have transformed the treatment of multiple myeloma, and doubled the overall survival of patients.[i] This extraordinary progress is unmatched in cancer care, but clearly more needs to be done if we are to realize the goal of making myeloma a chronic condition," said N. Anthony Coles, M.D., President and Chief Executive Officer of Onyx Pharmaceuticals. "Onyx is committed to supporting continued progress through education, research and partnerships, and urges everyone who has been impacted to make their mark in the quest to conquer this devastating disease."
The Make Your Mark at the Multiple Myeloma Experience booth at ASH (#2049) will feature insights from healthcare professionals and patients on what progress means to them, and a digital pledge wall where visitors can pledge their personal commitment to continuing the momentum in multiple myeloma. Those who are unable to attend the meeting will also be able to pledge their commitment and find out more about the experience by visiting www.makeyourmark-mm.com. Follow Make Your Mark on Twitter at @MakeYourMark_MM or by searching #MYMmm for updates from the meeting.
About Multiple Myeloma
Multiple myeloma is the second most common hematologic cancer and results from an abnormality of plasma cells, usually in the bone marrow. In the United States, more than 50,000 people are living with multiple myeloma and approximately 20,000 new cases are diagnosed annually.[ii]Worldwide, more than 210,000 people are living with multiple myeloma and approximately 100,000 new cases are diagnosed annually.[iii]
About Onyx Pharmaceuticals, Inc.
Based in South San Francisco, California, Onyx Pharmaceuticals, Inc. is a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer. The company is focused on developing novel medicines that target key molecular pathways. For more information about Onyx, visit the company's website at www.onyx.com.
[i] CancerCare Connect Booklet 2011
[ii] American Cancer Society, Cancer Facts & Figures 2012
[iii]International Agency for Research on Cancer, GLOBOCAN 2008
SOURCE Onyx Pharmaceuticals, Inc.